Does NovaPharm currently hold a WDA(H)?

NovaPharm does not publish a claim that it holds a WDA(H). The company is preparing its operating and quality systems and will not commence regulated wholesale supply until the required authorisation is in place.

Does NovaPharm hold PLPI product licences?

No product-specific PLPI licence is represented as granted on this website. PLPI is a strategic pathway under regulatory preparation and each product would require the applicable MHRA approval.

Can a third-party logistics provider carry all regulatory responsibility?

No. Outsourced providers perform agreed activities, while the pharmaceutical company must define, qualify and oversee the relationship and retain its applicable responsibilities.

Regulatory & Quality

No regulated supply before the required permissions.

The NovaPharm pathway connects company authority, product responsibility, quality systems and release evidence in a sequence that can be reviewed.

Discuss regulatory readiness

Regulatory foundation

A roadmap built around accountable gates.

Each stage has its own evidence, owner and completion criteria. Progress in one stage does not silently satisfy another.

01WDA(H) application readiness
Evidence, accountable ownership and unresolved risks remain visible.
02Product-specific PLPI assessment
Evidence, accountable ownership and unresolved risks remain visible.
03QMS and SOP governance
Evidence, accountable ownership and unresolved risks remain visible.
04GDP and vendor oversight
Evidence, accountable ownership and unresolved risks remain visible.
05Pharmacovigilance and recall readiness
Evidence, accountable ownership and unresolved risks remain visible.
06Batch and document integrity
Evidence, accountable ownership and unresolved risks remain visible.
07Commercial release only after applicable authorisation
Release follows the applicable permission and completed operating controls.

Batch integrity

Evidence should travel with every governed product and transaction.

Product identity, source, status, documentation, conditions and decision history need a consistent chain of evidence.

Review the Trust Centre

Pharmaceutical packaging and controlled batch documentation — Representative traceability context; no active NovaPharm batch or inventory is depicted.